Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 84

1.

Use of lanreotide for the treatment of gastrointestinal fistulae.

Clive K, Hardin M, White C, Larson C, Oh J, Cohn S.

Ann Surg. 2011 Jan;253(1):211; author reply 211-2. doi: 10.1097/SLA.0b013e3182050c1f. No abstract available.

PMID:
21135689
[PubMed - indexed for MEDLINE]
2.

Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog lanreotide.

Raderer M, Hejna MH, Kurtaran A, Kornek GV, Valencak JB, Oberhuber G, Vorbeck F, Virgolini I, Scheithauer W.

Am J Gastroenterol. 1999 Jan;94(1):278-9.

PMID:
9934776
[PubMed - indexed for MEDLINE]
3.

[Lanreotide++: a new therapeutic option in acromegaly].

Díez JJ.

Med Clin (Barc). 1996 Sep 7;107(7):257-69. Review. Spanish. No abstract available.

PMID:
8975096
[PubMed - indexed for MEDLINE]
4.

[Excellent response to lanreotide treatment of thyrotropin and prolactin secreting pituitary macroadenoma].

Murillo Sanchís J, Martín AL, Salinas Vert I, Sanmartí Sala A.

Med Clin (Barc). 2000 Feb 19;114(6):238. Spanish. No abstract available.

PMID:
10757110
[PubMed - indexed for MEDLINE]
5.

[Partial regression of a desmoid tumor after prolonged treatment with lanreotide].

Mannant PR, Beau P, De Lédinghen V, Barrioz T, Genestin E.

Gastroenterol Clin Biol. 1995 Dec;19(12):1072-3. French. No abstract available.

PMID:
8729428
[PubMed - indexed for MEDLINE]
6.

Randomized, placebo-controlled, double-blind study of the efficacy of lanreotide 30 mg PR in the treatment of pancreatic and enterocutaneous fistulae.

Gayral F, Campion JP, Regimbeau JM, Blumberg J, Maisonobe P, Topart P, Wind P; Lanreotide Digestive Fistula.

Ann Surg. 2009 Dec;250(6):872-7.

PMID:
19953707
[PubMed - indexed for MEDLINE]
7.

[Complete regression of a somatotropin-secreting adenoma with lanreotide monotherapy].

Ilias I, Mastorakos G.

Presse Med. 2000 Nov 4;29(33):1818-9. French. No abstract available.

PMID:
11109436
[PubMed - indexed for MEDLINE]
8.

[Peritoneal mesothelioma: long survival with intraperitoneal chemotherapy, lanreotide and mucolytics].

Montmayeur G, Thivat E, Gimbergues P, Dib M, Leheurteur M, Curé H, Chollet P, Durando X.

Gastroenterol Clin Biol. 2008 Oct;32(10):874-5. doi: 10.1016/j.gcb.2007.11.010. Epub 2008 Mar 18. French. No abstract available.

PMID:
18353584
[PubMed - indexed for MEDLINE]
Free Article
9.

Slow-release lanreotide treatment in endocrine gastrointestinal tumors.

Tomassetti P, Migliori M, Gullo L.

Am J Gastroenterol. 1998 Sep;93(9):1468-71.

PMID:
9732927
[PubMed - indexed for MEDLINE]
10.

High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects.

Eriksson B, Renstrup J, Imam H, Oberg K.

Ann Oncol. 1997 Oct;8(10):1041-4.

PMID:
9402179
[PubMed - indexed for MEDLINE]
Free Article
11.

Somatostatin receptor scintigraphy during treatment with lanreotide in patients with neuroendocrine tumors.

Janson ET, Kälkner KM, Eriksson B, Westlin JE, Oberg K.

Nucl Med Biol. 1999 Nov;26(8):877-82.

PMID:
10708300
[PubMed - indexed for MEDLINE]
12.

Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results.

Raderer M, Hamilton G, Kurtaran A, Valencak J, Haberl I, Hoffmann O, Kornek GV, Vorbeck F, Hejna MH, Virgolini I, Scheithauer W.

Br J Cancer. 1999 Feb;79(3-4):535-7.

PMID:
10027326
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Lanreotide for the treatment of acromegaly.

Castinetti F, Saveanu A, Morange I, Brue T.

Adv Ther. 2009 Jun;26(6):600-12. doi: 10.1007/s12325-009-0035-4. Epub 2009 Jun 16. Review.

PMID:
19533047
[PubMed - indexed for MEDLINE]
14.

[Effect of lanreotide on prolactin level in patients with pituitary mixed tumors].

Wasko R, Sawicka J, Stachowiak C, Kozak W, Junik R, Sowinski J.

Ann Endocrinol (Paris). 2002 Dec;63(6 Pt 1):532-5. French.

PMID:
12527855
[PubMed - indexed for MEDLINE]
15.

Preoperative lanreotide treatment for GH-secreting pituitary adenomas: effect on tumour volume and predictive factors of significant tumour shrinkage.

Lucas T, Astorga R, Catalá M; Spanish Multicentre Lanreotide Study Group on Acromegaly.

Clin Endocrinol (Oxf). 2003 Apr;58(4):471-81.

PMID:
12641631
[PubMed - indexed for MEDLINE]
16.

Short- and long-term effect of a long-acting somatostatin analogue, lanreotide (SR-L) on metastatic gastrinoma.

Gaztambide S, Vazquez JA.

J Endocrinol Invest. 1999 Feb;22(2):144-6.

PMID:
10195383
[PubMed - indexed for MEDLINE]
17.

Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.

Karavitaki N, Turner HE, Adams CB, Cudlip S, Byrne JV, Fazal-Sanderson V, Rowlers S, Trainer PJ, Wass JA.

Clin Endocrinol (Oxf). 2008 Jun;68(6):970-5. Epub 2007 Nov 19.

PMID:
18031313
[PubMed - indexed for MEDLINE]
18.

[Lanreotide in the treatment of the dumping syndrome].

Alcalde Rubio M, Carro Rosell J, Morales Pérez F.

Rev Esp Enferm Dig. 1999 Mar;91(3):223-4. Spanish. No abstract available.

PMID:
10231313
[PubMed - indexed for MEDLINE]
19.

The future of somatostatin analogue therapy.

Stewart PM, James RA.

Baillieres Best Pract Res Clin Endocrinol Metab. 1999 Oct;13(3):409-18. Review.

PMID:
10909432
[PubMed - indexed for MEDLINE]
20.

Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.

O'Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouché O, Catus F, Blumberg J, Ruszniewski P.

Cancer. 2000 Feb 15;88(4):770-6.

PMID:
10679645
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk